Vasoplegia is defined as sustained low systemic vascular resistance in the context of a normal or high cardiac index, leading ...

Budoprutug receives FDA Fast Track status for primary membranous nephropathy after phase 1b data demonstrate clinical activity and safety.

A new study published in the Journal of the American Medical Association found fewer than 25% (21.2%) of ...

Stopping RAS inhibitors after eGFR decline may raise risk of kidney failure and death. Learn more about this new study.

Monthly injections of tonlamarsen lowered AGT but didn’t reduce BP in patients already on multiple antihypertensive drugs.

Most US veterans who have new heart failure with reduced ejection fraction do not receive all four classes of ...

Tonlamarsen “suppresses hepatic angiotensinogen production,” Laffin told the media ahead of the late-breaking session. “We know that AGT suppression reduces blood pressure among patients taking zero ...

At the 2026 ACC Scientific Session, the phase II KARDINAL trial tested tonlamarsen in adults with uncontrolled hypertension, ...

The phase 2 ASSIST trial showed that atrasentan has an additional antiproteinuric effect -- approximately 25% -- over 12 weeks in patients with earlier-stage IgA nephropathy already receiving ...

Fast Track Designation recognizes both the urgent need for new therapies in pMN and the compelling early clinical activity generated to date with budoprutug,” said Edgar Charles, M.D., Chief Medical ...

Kardigan(TM), a clinical-stage precision therapeutics company developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist, today announced ...

Kardigan’s tonlamarsen reduced a key biomarker for hypertension in a phase 2 trial, but missed the study’s other goal of significantly reducing blood pressure. The biotech evaluated monthly 90 mg ...